Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
about
Patient-derived tumour xenografts as models for oncology drug developmentUse of rodents as models of human diseasesProteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approachDll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenograftsA Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Recent advances in vascular disrupting agents in cancer therapy.Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
P2860
Q24604068-78598B72-4FD7-42D5-8267-F0BC6F54E53EQ26822856-2FA23AAE-8428-4972-B4B9-85B345B6218FQ28388409-8981636C-5216-4934-BE36-80BDE5B74A0BQ35418092-C5EB2F9A-BB3D-4A1C-ACF3-02854DD7D65CQ35920803-D13D4B7B-6012-4E9B-B881-B4AEBC0819D2Q36213741-1A3F6A7B-F212-4A5A-B333-4A3EFA22A279Q38264533-E5C4FEA1-4567-4D6C-B116-7A2F450BABEBQ39255433-53DC3205-C8A0-4381-9E24-977A0D2F7AB4Q47099537-638EF850-2B8F-4ACA-885B-5A6BC6701E16Q47600932-3176038B-A31A-4E74-92F8-4E130735504C
P2860
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
@en
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
@nl
type
label
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
@en
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
@nl
prefLabel
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
@en
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
@nl
P2093
P2860
P1476
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
@en
P2093
Gissou Azabdaftari
Hans Hammers
Kristin Lehet
Leigh Ellis
Mukund Seshadri
Paula Sotomayor
Preeti Shah
Roberto Pili
P2860
P304
P356
10.1158/1535-7163.MCT-11-0748
P577
2011-11-14T00:00:00Z